Vaccine Development Platforms

Viral vectored Vaccine Technologies have emerged as a promising platform, leveraging the intrinsic adjuvant properties of viruses to deliver recombinant antigens. Adenovirus and poxvirus vectors have demonstrated strong immunogenicity in clinical trials for various pathogens including influenza, Ebola, HIV etc.Self-amplifying RNA and DNA vaccines are novel platforms that avoid the expense and complexity of viral vector production. They rely on host cell transcription and translation machinery to produce antigen in situ; minimizing manufacturing requirements.

Plant-derived vaccine production offers scalable, low cost alternatives to conventional egg and cell culture based methods. Plants act as bioreactors to produce vaccine antigens either by transient expression or stable transformation approaches. The recent licensure of a plant-produced Norovirus vaccine validates this technology.